National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting, 37887 [2017-17040]
Download as PDF
Federal Register / Vol. 82, No. 155 / Monday, August 14, 2017 / Notices
harmonization of new, revised, and
alternative toxicological test methods.
Additional information about SACATM,
including the charter, roster, and
records of past meetings, can be found
at https://ntp.niehs.nih.gov/go/167.
Dated: August 1, 2017.
John R. Bucher,
Associate Director, National Toxicology
Program.
Dated: August 8, 2017.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
DEPARTMENT OF HOMELAND
SECURITY
[FR Doc. 2017–17040 Filed 8–11–17; 8:45 am]
[Docket No. USCG–2017–0194]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[FR Doc. 2017–17036 Filed 8–11–17; 8:45 am]
Substance Abuse and Mental Health
Services Administration
BILLING CODE 4140–01–P
37887
Coast Guard
Waterway Suitability Assessment for
Operation of Liquefied Hazardous Gas
Terminal; Port Arthur, TX
Coast Guard, DHS.
Notice and request for
comments.
AGENCY:
ACTION:
In accordance with Coast
Guard regulations, Lynx Terminals LLC
(Lynx Terminals) has submitted a Letter
of Intent and Preliminary Waterway
Suitability Assessment to the Coast
Guard Captain of the Port, Port Arthur,
TX (COTP) regarding the company’s
plans to handle and transport Liquefied
Hazardous Gas (LHG) at the Port of Port
Arthur docks in Port Arthur, TX. The
Coast Guard is notifying the public of
this proposed increase in LHG marine
traffic on the Sabine-Neches Waterway
and is soliciting comments relevant to
the Coast Guard’s preparation of a Letter
of Recommendation (LOR) for issue to
the federal, state or local agency with
jurisdiction over the proposed facility.
DATES: Comments and related material
must be received on or before
September 13, 2017.
ADDRESSES: You may submit comments
identified by docket number USCG–
2017–0194 using the Federal
eRulemaking Portal at https://
www.regulations.gov. See the ‘‘Public
Participation and Request for
Comments’’ portion of the
SUPPLEMENTARY INFORMATION section
below for further instructions on
submitting comments.
FOR FURTHER INFORMATION CONTACT: If
you have questions on this notice, call
or email Commander Loan T. O’Brien,
U.S. Coast Guard; telephone 409–723–
6564, email: Loan.T.O’Brien@uscg.mil.
SUPPLEMENTARY INFORMATION:
SUMMARY:
Notice of Meeting
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
sradovich on DSK3GMQ082PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel NIAID Clinical Trial
Planning Grant (R34), Implementation
Cooperative Agreement (U01) and SBIR
Phase II Implementation Cooperative
Agreement (U44).
Date: September 12, 2017.
Time: 10:00 a.m. to 3:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health 5601
Fishers Lane, Rockville, MD 20892
(Telephone Conference Call).
Contact Person: Maryam Feili-Hariri,
Ph.D., Scientific Review Officer Scientific
Review Program Division of Extramural
Activities, National Institutes of Health/
NIAID, 5601 Fishers Lane, Rockville, MD
20852, 240–669–5026, haririmf@
niaid.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
VerDate Sep<11>2014
16:45 Aug 11, 2017
Jkt 241001
Pursuant to Public Law 92–463,
notice is hereby given that the
Substance Abuse and Mental Health
Services Administration’s (SAMHSA)
Center for Substance Abuse Prevention
(CSAP) National Advisory Council will
meet on August 25, 2017, 10:00 a.m.–
11:00 a.m., in Rockville, MD.
The meeting will include the review,
discussion, and evaluation of grant
applications reviewed by the Initial
Review Group, and involve an
examination of confidential financial
and business information as well as
personal information concerning the
applicants. Therefore, this meeting will
be closed to the public as determined by
the Acting Deputy Assistant Secretary
for Mental Health and Substance Use, in
accordance with Title 5 U.S.C.
552b(c)(4) and (c)(6) and 5 U.S.C. App.
2, Section 10(d).
Committee Name: Substance Abuse
and Mental Health Services
Administration, Center for Substance
Abuse Prevention National Advisory
Council.
Date/Time/Type: August 25, 2017,
10:00 a.m.–11:00 a.m. (Closed).
Place: SAMHSA Building, 5600
Fishers Lane, Rockville, MD 20852.
Contact: Matthew J. Aumen,
Designated Federal Officer, SAMHSA/
CSAP National Advisory Council, 5600
Fishers Lane, Rockville, MD 20852,
Email: Matthew.Aumen@
samhsa.hhs.gov.
Carlos R. Castillo,
Committee Management Officer, SAMHSA.
[FR Doc. 2017–17074 Filed 8–11–17; 8:45 am]
BILLING CODE 4162–20–P
PO 00000
Frm 00049
Fmt 4703
Sfmt 4703
Public Participation and Request for
Comments
We encourage you to submit
comments and related material in
response to this notice through the
Federal eRulemaking Portal at https://
www.regulations.gov. We will consider
all submissions and may adjust our final
action based on your comments. If you
submit a comment, please include the
docket number for this notice, indicate
the specific section of this document to
which each comment applies, and
provide a reason for each suggestion or
recommendation.
We encourage you to submit
comments through the Federal
E:\FR\FM\14AUN1.SGM
14AUN1
Agencies
[Federal Register Volume 82, Number 155 (Monday, August 14, 2017)]
[Notices]
[Page 37887]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-17040]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and Infectious Diseases; Notice of
Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Allergy and Infectious
Diseases Special Emphasis Panel NIAID Clinical Trial Planning Grant
(R34), Implementation Cooperative Agreement (U01) and SBIR Phase II
Implementation Cooperative Agreement (U44).
Date: September 12, 2017.
Time: 10:00 a.m. to 3:30 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health 5601 Fishers Lane,
Rockville, MD 20892 (Telephone Conference Call).
Contact Person: Maryam Feili-Hariri, Ph.D., Scientific Review
Officer Scientific Review Program Division of Extramural Activities,
National Institutes of Health/NIAID, 5601 Fishers Lane, Rockville,
MD 20852, 240-669-5026, haririmf@niaid.nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.855,
Allergy, Immunology, and Transplantation Research; 93.856,
Microbiology and Infectious Diseases Research, National Institutes
of Health, HHS)
Dated: August 8, 2017.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2017-17040 Filed 8-11-17; 8:45 am]
BILLING CODE 4140-01-P